Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 9/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252562 | 0.86 | NR4A2 (0.46) | KDM4E | |
| Hydrochloric Acid SCHEMBL429203 | 0.85 | NR4A2 (0.45) | KDM4E | |
| SCHEMBL5012191 | 0.81 | HDAC1 (0.43) | HDAC1HDAC8HDAC6L3MBTL1OPRM1 | |
| SCHEMBL10252626 | 0.81 | GAA (0.43) | HDAC1HDAC8HDAC6L3MBTL1GAA | |
| SCHEMBL422988 | 0.80 | CYP11B2 (0.40) | L3MBTL1OPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL5014020 | 0.77 | KDM4E (0.48) | HDAC1HDAC8HDAC6GAAKDM4E | |
| SCHEMBL10252622 | 0.77 | LMNA (0.36) | L3MBTL1OPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL424229 | 0.77 | CYP11B2 (0.38) | L3MBTL1OPRD1ALOX15ALDH1A1 | |
| SCHEMBL5015627 | 0.75 | GAA (0.40) | HDAC1HDAC8HDAC6L3MBTL1OPRM1 | |
| SCHEMBL5013552 | 0.75 | OPRM1 (0.39) | HDAC1HDAC8HDAC6L3MBTL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | claimed |
| WO-2008127613-A1 | NEW PHARMACEUTICAL COMPOSITIONS | SCYNEXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | NSUN2, TPMT, EIF5B | HDAC1 4007/4885HDAC8 4559/4885HDAC6 2995/4885 |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | IRF3, HAVCR2, ZC3HAV1 | HDAC1 150/4885HDAC8 736/4885HDAC6 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.